Cover Image
市場調查報告書

氣喘:流行病學、病患人數的市場預測,治療流程,已上市/開發平台藥物分析

Asthma: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365207
出版日期 內容資訊 英文 429 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
氣喘:流行病學、病患人數的市場預測,治療流程,已上市/開發平台藥物分析 Asthma: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年05月01日 內容資訊: 英文 429 Pages
簡介

全球氣喘治療藥市場上今後,各種生技藥品將上市。但,一般認為實際被處方將限定給重病患者。

本報告提供已上市/臨床實驗中 (開發平台上)的氣喘疫苗相關分析,各產品的市場規模的估計值,各國市場趨勢預測 (今後10年份) ,及開發中產品和現有藥物,以及開發中產品的競爭預測,品牌藥的專利到期造成的負面影響等相關調查。

美國、日本、歐洲主要5個國家的氣喘治療藥的市場預測

  • 摘要整理
  • 市場概要與趨勢
  • 市場定義和分析方法
  • 各品牌的市場預測
  • Advair (fluticasone/salmeterol)
  • benralizumab
  • Breo (fluticasone furoate/vilanterol)
  • Cinqair (reslizumab)
  • Dulera (mometasone/formoterol)
  • Flutiform (fluticasone/formoterol)
  • Nucala (mepolizumab)
  • Singulair (montelukast)
  • Spiriva (tiotropium)
  • Symbicort (budesonide/formoterol)
  • Xolair (omalizumab)
  • 一次調查技術

治療方法:氣喘

  • 摘要整理
  • 一次調查技術
  • 疾病定義與診斷方法
  • 患者的分類
  • 各國治療系統
  • 目前治療選擇
  • 處方的趨勢
  • 學名藥的影響度
  • 氣喘相關的未滿足需求

流行病學:氣喘

  • 摘要整理
  • 疾病的背景情況
  • 資訊來源、分析方法
  • 市場預測
  • 流行病學者的見解
  • 分析的優勢與限制

已上市藥物:氣喘

  • 摘要整理
  • 產品概要
  • 產品簡介:Advair
  • 產品簡介:Asmanex
  • 產品簡介:Breo
  • 產品簡介:Cinqair
  • 產品簡介:Dulera
  • 產品簡介:Flovent
  • 產品簡介:Flutiform
  • 產品簡介:Nucala
  • 產品簡介:Pulmicort
  • 產品簡介:Singulair
  • 產品簡介:Spiriva
  • 產品簡介:Symbicort
  • 產品簡介:Xolair

開發中產品:氣喘

  • 摘要整理
  • 臨床實驗開發平台概要
  • 在早期階段的機會
  • 治療方法比較
  • 臨床實驗的設計
  • 產品簡介 (最後階段):QVM149
  • 產品簡介 (最後階段):benralizumab
  • 產品簡介 (最後階段):dupilumab
  • 產品簡介 (最後階段):lebrikizumab
  • 產品簡介 (最後階段):masitinib
  • 產品簡介 (最後階段):tralokinumab

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5962

The increasing availability of biologics will drive growth in the asthma market during 2015-24, but prescribing will be restricted to patients with severe persistent uncontrolled asthma.

This report addresses the following questions:

  • Where will the newly approved Nucala and Cinqair be positioned in the treatment algorithm and will they directly compete with Xolair?
  • What are pulmonologists' views on the late-phase interleukin (IL) inhibitors and how will they differentiate between them?
  • What clinical endpoints do pulmonologists want to see in trial programs of biologics?
  • How will the loss of brand exclusivity impact leading inhaled corticosteroid/long-acting beta 2 agonist (ICS/LABA) inhalers?

TABLE OF CONTENTS

FORECAST: ASTHMA IN THE US, JAPAN, AND 5EU

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. Brand Forecasts
  • 5. Advair (fluticasone/salmeterol)
  • 6. benralizumab
  • 7. Breo (fluticasone furoate/vilanterol)
  • 8. Cinqair (reslizumab)
  • 9. Dulera (mometasone/formoterol)
  • 10. Flutiform (fluticasone/formoterol)
  • 11. Nucala (mepolizumab)
  • 12. Singulair (montelukast)
  • 13. Spiriva (tiotropium)
  • 14. Symbicort (budesonide/formoterol)
  • 15. Xolair (omalizumab)
  • 16. Primary Research Methodology

TREATMENT: ASTHMA

  • 17. Executive Summary
  • 18. Primary Research Methodology
  • 19. Disease Definition and Diagnosis
  • 20. Patient Segmentation
  • 21. Country Treatment Trees
  • 22. Current Treatment Options
  • 23. Prescribing Trends
  • 24. Impact of Generics
  • 25. Unmet Needs in Asthma

EPIDEMIOLOGY: ASTHMA

  • 26. Executive Summary
  • 27. Disease Background
  • 28. Sources and Methodology
  • 29. Forecast
  • 30. Epidemiologist Insight
  • 31. Strengths and Limitations

MARKETED DRUGS: ASTHMA

  • 32. Executive Summary
  • 33. Product Overview
  • 34. Product profile: Advair
  • 35. Product profile: Asmanex
  • 36. Product profile: Breo
  • 37. Product profile: Cinqair
  • 38. Product profile: Dulera
  • 39. Product profile: Flovent
  • 40. Product profile: Flutiform
  • 41. Product profile: Nucala
  • 42. Product profile: Pulmicort
  • 43. Product profile: Singulair
  • 44. Product profile: Spiriva
  • 45. Product profile: Symbicort
  • 46. Product profile: Xolair

PIPELINE: ASTHMA

  • 47. Executive Summary
  • 48. Clinical Pipeline Overview
  • 49. Early-Phase Opportunities
  • 50. Comparator Therapy
  • 51. Clinical Trial Design
  • 52. Product profile (late stage): QVM149
  • 53. Product profile (late stage): benralizumab
  • 54. Product profile (late stage): dupilumab
  • 55. Product profile (late stage): lebrikizumab
  • 56. Product profile (late stage): masitinib
  • 57. Product profile (late stage): tralokinumab
Back to Top